AICAR vs MOTS-c
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Acadesine, AICA riboside
AICAR is not a peptide at all. It is a small nucleoside (a building block related to the purine pathway) that cells convert into ZMP, a molecule that mimics AMP and switches on AMPK, the cell's energy sensor. It became famous in 2008 when a Salk Institute study showed sedentary mice on AICAR ran 44% further, earning it the "exercise in a pill" label. Human data tell a much less exciting story: it was tested as an intravenous drug (acadesine) for heart surgery and leukemia, the big heart trial failed, and nothing is approved.
Also: Mitochondrial ORF of the 12S rRNA type-c
MOTS-c is a 16-amino-acid peptide your own mitochondria make, encoded inside the 12S rRNA region of mitochondrial DNA and discovered in 2015. It is studied as a metabolic regulator and a so-called exercise mimetic, because its levels rise when you work out and it improves insulin sensitivity in animals. The catch: the impressive results are almost entirely in mice, with no completed published human efficacy trials.
Key Comparison Insights
- AICAR is categorized as Metabolic, while MOTS-c is Hormonal.
- AICAR has stronger research evidence (Human Trials) compared to MOTS-c (Animal Studies).
Detailed Comparison
| Attribute | AICAR | MOTS-c |
|---|---|---|
| Category | Metabolic | Hormonal |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Once inside cells, AICAR is phosphorylated to ZMP (AICAR monophosphate), which behaves like AMP and activates AMP-activated protein kinase (AMPK). AMPK is the master switch cells flip when energy runs low: it pushes glucose uptake and fat oxidation up and energy-costly processes like fat and protein synthesis down. In mouse muscle, AMPK activation by AICAR turned on a set of oxidative, endurance-type genes overlapping with those controlled by PPAR-delta. The catch is that ZMP is not a clean AMPK switch: it also affects other AMP-sensitive enzymes and the adenosine system, which is why acadesine was originally developed as an "adenosine regulating agent" for the heart. Effects in mice also do not automatically translate to people. A 2011 human study found that IV AICAR during an insulin clamp caused vasodilation (higher heart rate, lower blood pressure) but no direct effect on glucose uptake. | MOTS-c works largely through the AMPK pathway, the cell's main energy and fuel-gauge system. The proposed route is that MOTS-c interferes with the folate-AICAR-one-carbon metabolism cycle, which raises AICAR and activates AMPK in skeletal muscle, liver, and fat. Once AMPK is switched on, cells burn more fatty acids, take up more glucose, and ramp up mitochondrial biogenesis. MOTS-c can also move into the cell nucleus under metabolic stress and influence stress-response genes, which is unusual for a mitochondrial peptide and is part of why it is framed as a stress-adaptive signal. Treat the exact pathway details as a working model rather than settled fact, since much of it is still being mapped. |
| Common Dosing | No established dose; human data are IV infusions only Single infusions or short cycles in trials | 5-10 mg weekly 1-3x weekly |
| Administration | Intravenous infusion in human trials; intraperitoneal injection in mice | Subcutaneous injection |
| Typical Duration | Single infusions or short cycles in human trials; 4 weeks in the mouse endurance study | Variable by protocol |
| Best Time to Take | No evidence-based timing in healthy people | Morning or pre-workout |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The headline study is Narkar and colleagues (Cell, 2008): four weeks of AICAR at 500 mg/kg/day by injection in untrained mice induced metabolic genes and increased running endurance by 44%. That paper is the source of nearly all the hype, and it was in mice at a huge dose. Human work is a different picture. As acadesine, it went into the RED-CABG phase 3 trial (JAMA 2012), giving 0.1 mg/kg/min IV for 7 hours around bypass surgery. The trial was stopped for futility after 3,080 patients: the primary outcome was 5.1% with acadesine versus 5.0% with placebo, so no benefit. A phase I/II study in relapsed chronic lymphocytic leukemia (Van Den Neste et al., Cancer Chemotherapy and Pharmacology) set the maximum tolerated single IV dose at 210 mg/kg; at 315 mg/kg two of three patients had dose-limiting toxicity (tumor lysis syndrome and kidney injury), and hyperuricemia was a recurring problem that required allopurinol. There are no human trials showing AICAR improves endurance, body composition, or longevity in healthy people. It is also one of the more catchable doping agents: anti-doping labs use carbon isotope ratio testing to separate injected AICAR from the body's natural AICAR. | In mice, MOTS-c is genuinely impressive: it improves insulin sensitivity, protects against diet-induced obesity, and older animals given MOTS-c run longer on a treadmill, which is where the exercise-mimetic label comes from. The human story is much thinner. The strongest human finding is observational: exercise raises MOTS-c, with reports of roughly a 12-fold jump in skeletal muscle and about a 1.6-fold rise in circulation after exercise, suggesting it may be one natural messenger behind some exercise benefits. But that is correlation, not proof that injecting MOTS-c reproduces those benefits. As of 2026 there are no completed, published randomized human trials showing that supplemental MOTS-c causes weight loss, better metabolic health, or longer life in people. It is also a known anti-doping target, which tells you it is treated as experimental and performance-relevant, not as an established therapy. |
Frequently Asked Questions: AICAR vs MOTS-c
What is the difference between AICAR and MOTS-c?
AICAR is a metabolic peptide that aicar is not a peptide at all. it is a small nucleoside (a building block related to the purine pathway) that cells convert into zmp, a molecule that mimics amp and switches on ampk, the cell's energy sensor. it became famous in 2008 when a salk institute study showed sedentary mice on aicar ran 44% further, earning it the "exercise in a pill" label. human data tell a much less exciting story: it was tested as an intravenous drug (acadesine) for heart surgery and leukemia, the big heart trial failed, and nothing is approved. MOTS-c is a hormonal peptide that mots-c is a 16-amino-acid peptide your own mitochondria make, encoded inside the 12s rrna region of mitochondrial dna and discovered in 2015. it is studied as a metabolic regulator and a so-called exercise mimetic, because its levels rise when you work out and it improves insulin sensitivity in animals. the catch: the impressive results are almost entirely in mice, with no completed published human efficacy trials. The main differences lie in their mechanisms of action and clinical applications.
Which is better, AICAR or MOTS-c?
Neither is universally "better" - the choice depends on your specific goals. AICAR is typically used for metabolic purposes, while MOTS-c is used for hormonal. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can AICAR and MOTS-c be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using AICAR and MOTS-c together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.